DK3326644T3 - Rekombinante clostridium botulinum-neurotoksiner - Google Patents

Rekombinante clostridium botulinum-neurotoksiner Download PDF

Info

Publication number
DK3326644T3
DK3326644T3 DK17201198.3T DK17201198T DK3326644T3 DK 3326644 T3 DK3326644 T3 DK 3326644T3 DK 17201198 T DK17201198 T DK 17201198T DK 3326644 T3 DK3326644 T3 DK 3326644T3
Authority
DK
Denmark
Prior art keywords
clostridium botulinum
botulinum neurotoxins
recombinant clostridium
recombinant
neurotoxins
Prior art date
Application number
DK17201198.3T
Other languages
Danish (da)
English (en)
Inventor
Aimee Cossins
Matthew Beard
Philip Marks
Original Assignee
Ipsen Bioinnovation Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd, Ipsen Biopharm Ltd filed Critical Ipsen Bioinnovation Ltd
Application granted granted Critical
Publication of DK3326644T3 publication Critical patent/DK3326644T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17201198.3T 2012-10-31 2013-10-31 Rekombinante clostridium botulinum-neurotoksiner DK3326644T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
EP13811605.8A EP2914282B1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
DK3326644T3 true DK3326644T3 (da) 2020-05-11

Family

ID=47358958

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17201198.3T DK3326644T3 (da) 2012-10-31 2013-10-31 Rekombinante clostridium botulinum-neurotoksiner
DK13811605.8T DK2914282T3 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13811605.8T DK2914282T3 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins

Country Status (26)

Country Link
US (1) US10030238B2 (cg-RX-API-DMAC10.html)
EP (3) EP3673914B1 (cg-RX-API-DMAC10.html)
JP (2) JP2019068823A (cg-RX-API-DMAC10.html)
KR (2) KR102264478B1 (cg-RX-API-DMAC10.html)
CN (2) CN110499321A (cg-RX-API-DMAC10.html)
AR (2) AR093309A1 (cg-RX-API-DMAC10.html)
AU (3) AU2013340610B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015005384A2 (cg-RX-API-DMAC10.html)
CA (1) CA2885519A1 (cg-RX-API-DMAC10.html)
DK (2) DK3326644T3 (cg-RX-API-DMAC10.html)
EA (1) EA201590794A8 (cg-RX-API-DMAC10.html)
ES (2) ES2788199T3 (cg-RX-API-DMAC10.html)
GB (1) GB201219602D0 (cg-RX-API-DMAC10.html)
HU (2) HUE048802T2 (cg-RX-API-DMAC10.html)
IL (1) IL237623B (cg-RX-API-DMAC10.html)
IN (1) IN2015MN00436A (cg-RX-API-DMAC10.html)
MX (2) MX367080B (cg-RX-API-DMAC10.html)
NO (1) NO2914282T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ705575A (cg-RX-API-DMAC10.html)
PL (2) PL3326644T3 (cg-RX-API-DMAC10.html)
PT (2) PT2914282T (cg-RX-API-DMAC10.html)
SG (2) SG10201701140WA (cg-RX-API-DMAC10.html)
TW (3) TWI673361B (cg-RX-API-DMAC10.html)
UA (1) UA118837C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014068317A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201501449B (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
RU2746736C2 (ru) * 2015-03-26 2021-04-20 Президент Энд Феллоуз Оф Гарвард Колледж Сконструированный ботулинический нейротоксин
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
EP3423084B1 (en) 2016-03-02 2021-09-01 Merz Pharma GmbH & Co. KGaA Composition comprising botulinum toxin
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018039506A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
ES2930237T3 (es) 2017-07-06 2022-12-09 Merz Pharma Gmbh & Co Kgaa Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos
EP3694489A4 (en) 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. METHOD AND COMPOSITION OF TOPICAL ADMINISTRATION
CN119020332A (zh) * 2018-01-29 2024-11-26 益普生生物制药有限公司 切割非神经元snare的肉毒杆菌神经毒素
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) * 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
WO2000002524A2 (en) 1998-07-10 2000-01-20 U.S. Army Medical Research Institute Of Infectious Diseases Botulinum neurotoxin vaccine
KR100876060B1 (ko) 1999-08-25 2008-12-26 알러간, 인코포레이티드 활성화가능한 재조합 신경독
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7825233B2 (en) * 2004-06-30 2010-11-02 Allergan, Inc. Optimizing expression of active Botulinum Toxin type E
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
MXPA06009853A (es) * 2005-03-03 2007-03-29 Allergan Inc Medios para bacteria de clostridium y procesos para obtener una toxina clostridial.
ES2369558T3 (es) * 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
JP2009543558A (ja) * 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
WO2009014854A1 (en) * 2007-07-26 2009-01-29 Allergan, Inc. Methods of activiting clostridial toxins
KR20160103551A (ko) 2008-12-10 2016-09-01 알러간, 인코포레이티드 클로스트리디움 독소 약제학적 조성물
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CN102481351B (zh) * 2009-04-14 2015-05-13 Mcw研究基金会股份有限公司 工程改造的肉毒杆菌神经毒素
SG181772A1 (en) * 2009-12-16 2012-07-30 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
WO2018039506A1 (en) * 2016-08-24 2018-03-01 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
KR102188539B1 (ko) 2020-12-09
UA118837C2 (uk) 2019-03-25
NO2914282T3 (cg-RX-API-DMAC10.html) 2018-05-19
IL237623A0 (en) 2015-04-30
EP3673914A1 (en) 2020-07-01
MX2019009222A (es) 2019-11-21
PT2914282T (pt) 2018-03-13
IL237623B (en) 2019-05-30
AU2018203556B2 (en) 2020-08-20
PL3326644T3 (pl) 2020-08-24
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20
SG11201502372SA (en) 2015-05-28
TW202012622A (zh) 2020-04-01
TW201435084A (zh) 2014-09-16
TWI673361B (zh) 2019-10-01
AU2013340610A1 (en) 2015-03-19
NZ705575A (en) 2019-08-30
WO2014068317A1 (en) 2014-05-08
CN110499321A (zh) 2019-11-26
AR117738A2 (es) 2021-08-25
HK1208359A1 (en) 2016-03-04
PL2914282T3 (pl) 2018-07-31
MX367080B (es) 2019-08-05
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
EA201590794A8 (ru) 2016-01-29
ZA201501449B (en) 2016-08-31
HUE048802T2 (hu) 2020-08-28
BR112015005384A2 (pt) 2017-08-08
EP3326644B1 (en) 2020-03-04
AU2013340610B2 (en) 2018-02-22
CN104755098A (zh) 2015-07-01
CA2885519A1 (en) 2014-05-08
SG10201701140WA (en) 2017-04-27
IN2015MN00436A (cg-RX-API-DMAC10.html) 2015-09-04
AR093309A1 (es) 2015-05-27
DK2914282T3 (en) 2018-02-26
KR20200110470A (ko) 2020-09-23
US10030238B2 (en) 2018-07-24
AU2018203556A1 (en) 2018-06-07
JP2020078321A (ja) 2020-05-28
EP2914282A1 (en) 2015-09-09
PT3326644T (pt) 2020-05-29
JP2019068823A (ja) 2019-05-09
ES2788199T3 (es) 2020-10-20
EP3326644A1 (en) 2018-05-30
KR20150094590A (ko) 2015-08-19
EP3673914B1 (en) 2021-10-27
AU2020244481A1 (en) 2020-10-29
KR102264478B1 (ko) 2021-06-15
MX2015005156A (es) 2015-09-23
TWI626307B (zh) 2018-06-11
US20150247139A1 (en) 2015-09-03
GB201219602D0 (en) 2012-12-12
TW201825680A (zh) 2018-07-16

Similar Documents

Publication Publication Date Title
DK3326644T3 (da) Rekombinante clostridium botulinum-neurotoksiner
HUE037310T2 (hu) Módosított botulinum neurotoxin
PT3584317T (pt) Enzima de clostridium histolyticum
PT3137621T (pt) Fabrico de neurotoxinas de clostridium botulinum recombinantes
HUE050037T2 (hu) Liofilizált botulinum toxin készítmény
DK3274364T3 (da) Modificeret botulinumneurotoksin
DK2889377T3 (da) Fc?RIIb-Specifik Fc-regionsvariant
DK3019190T3 (da) Kationiske neurotoksiner
EP2419128A4 (en) REMOVED BOTULINUM NEUROTOXIN
EP2807186A4 (en) DIFFICULT CLOSTRIDIUM VACCINES COMPRISING RECOMBINANT TOXINS
BR112014024373A2 (pt) anticorpos regulados por protease
FR2988733B1 (fr) Microorganisme recombinant
EP2920206A4 (en) MODIFIED APOL1 POLYPEPTIDE
HK40023045A (en) Solid compositions comprising recombinant clostridium botulinum neurotoxins
EP2937362A4 (en) RECOMBINANT PROTEIN